Skip to content

Efficacy and Safety of Different Antiviral Treatment timings in patients with HBV-related HCC who received immunotherapy

Efficacy and Safety of Different Antiviral Treatment timings in patients with HBV-related HCC who received immunotherapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600128297
Enrollment
Unknown
Registered
2026-07-17
Start date
2026-07-20
Completion date
Unknown
Last updated
2026-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cancer

Interventions

Observation group:No

Sponsors

The Fifth Medical Center of Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. The patient is at least 18 years old; 2. Pathologically diagnosed as hepatocellular carcinoma by liver biopsy, having received anti-hepatitis B virus treatment for at least 6 months before immunotherapy and achieved viral suppression, or initiating anti-hepatitis B virus treatment at the time of immunotherapy; 3. Child-Pugh classification is grade A or grade B (7); 4. ECOG PS score: 0–1 point; 5. There is at least one measurable target lesion according to the mRECIST standard.

Exclusion criteria

Exclusion criteria: 1. There are any serious comorbidities of other vital organs; 2. The patient has a history or current concurrent presence of other malignant tumors; 3. Those with incomplete medical records.

Design outcomes

Primary

MeasureTime frame
Overall survival ;

Secondary

MeasureTime frame
Incidence of HBV Reactivation;Progression-Free Survival;

Countries

China

Contacts

Public ContactLu Yinying

The Fifth Medical Center of Chinese PLA General Hospital

wwj19937751775@163.com+86 371 6639 9073

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026